Sept 2011: UK study on new CMV treatment gets funding

     
At the moment the main treatment available for congenital CMV  is Ganciclovir. However it is an invasive treatment for a newborn baby (it is administered via intraveinous drip), and in some cases it can cause adverse effects. Also, Ganciclovir treatment must be started before a baby is 4 weeks old, leaving a very small window  of opportunity to combat the possible effects of CMV, especially if it is not diagnosed immediately at birth. [singlepic id=59 w=250 float=left]A new study has just been awarded funding to test a less invasive oral antiviral called Valganciclovir. The study will  test 6 weeks of valgancyclovir treatment in infants aged 1-18 months old, significantly increasing the potential window for treating congenital CMV. Please email info@cmvaction.org.uk if you are interested in finding out more. &;

Tags: 

  • news
     

Our Stories

Joshua_newborn_CMV
When our youngest son was born in 2001, apart from a little jaundice he seemed 'normal'. It was only as time passed and developmental milestones were not reached, that concerns began. He... Read more
My name is Amanda and I’m 36 years old.   After 3 years of trying for a baby through 2 rounds of IVF, I conceived twins.  At 5 weeks I broke out in a rash all over my arms... Read more

Latest Events

Registered charity no: 1171773